• / Free eNewsletters & Magazine
  • / My Account
Home>SkinBioTherapeutics plc - Full Year Results

SkinBioTherapeutics plc - Full Year Results

SkinBioTherapeutics plc - Full Year Results

10/05/2017

SkinBioTherapeutics plc - Full Year Results

SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, has announced its full year results for the year to 30 June 2017.

Key highlights

  • Research agreement with the University of Manchester for ‘development of a bacterial lysate as a novel agent to combat infections’
  • Successful demonstration of the three modes of action of the SkinBiotix® technology
  • Creating a strong Board and management team for the development and commercial phase of the Company
  • Admission to AIM in April 2017 raising £4.5m
  • Initiating scale up of lysate manufacture with third parties
  • Cash as at 30 June 2017 £3.9m (2016: £0.3m)
  • Post year end: SkinBiotix® passed cytotoxicity test, representing first key milestone post IPO

Cath O’Neill, CEO of SkinBioTherapeutics, said:

“This has been a significant year for the Company; from creating the infrastructure and team to support the growth and development of the Company, to the scientific progress around our proprietary skin platform, SkinBiotix ® .

“During the year, we have demonstrated three significant properties – barrier improvement, anti-infection and repair – which form the foundations of our three development programmes. We are making good scientific headway and are starting initial discussions with partners.

“Operationally, we have made a good start to the new financial year, especially with the recent news around the third party cytotoxicity testing, and we look forward to reporting on the next phase of the Company’s journey.”

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

©2017 Morningstar Advisor. All right reserved.